spacer
home > epc > spring 2009 > beyond technology
PUBLICATIONS
European Pharmaceutical Contractor

Beyond Technology

As electronic data capture (EDC) is becoming the standard for clinical trials, CROs are under pressure to offer this system and carry out projects that competitively meet time, cost and quality demands. Decisions about the choice of EDC partner must take the sponsor’s interests into account in order to establish an efficient collaboration. EDC vendors are advised to offer special programmes for this purpose.

STRATEGIC EDC PARTNERSHIPS

According to Thomson CenterWatch, the proportion of EDC studies in 2007 exceeded the 40 per cent mark for the first time, with respect to all clinical studies commissioned worldwide (1). Furthermore, it is predicted that this technology will become the standard by 2010. Since further prognoses indicate that the market tends towards standardisation of EDC systems, many CROs choose not to develop their own system and instead work together with specialised EDC vendors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Claudia Horneck is the Director PR/Promotion of clinIT AG, but also works as a selfemployed Consultant working closely with pharmaceutical contract research organisations. She received her Masters in German Literature, Linguistics and Philosophy from the Albert-Ludwigs University, Freiburg, Germany. Prior to her position at clinIT AG, Claudia held the positions of Head of Sales Administration and Customer Relations Manager at Thomae & Partner AG, Freiburg.

spacer
Claudia Horneck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement